Septarna Inc. (SEPN)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Is Septerna a Stock to Sell After an Insider Let Go of 15,000 Shares?
15,000 shares were exercised and sold for a total of ~$533,000 on June 22, 2026, at a weighted average price of around $35.51 per share. This transaction impacted 13.46% of Long's direct Common Stock holdings, reducing his position to 96,412 shares.
Septerna, Inc. (SEPN) Reports Q1 Loss, Tops Revenue Estimates
Septerna, Inc. (SEPN) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to a loss of $0.49 per share a year ago.
Septerna, Inc. (SEPN) Reports Q4 Loss, Tops Revenue Estimates
Septerna, Inc. (SEPN) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.64 per share a year ago.
Septarna Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 30 | $317 | $1,017.45 | $700.45 | 220.96% |
 Joseph Castro Nuveen LLC | 29,176 | $385,656.84 | $993,442.8 | $607,785.96 | 157.6% |
 Candace Cavalier Congress Wealth Management LLC / DE / | 12,589 | $133,065.73 | $428,696.99 | $295,631.26 | 222.17% |
 Li Peng China Universal Asset Management Co. Ltd. | 11,946 | $326,701.98 | $405,277.61 | $78,575.63 | 24.05% |
 Ana-Maria Ignat Covestor Ltd | 2,260 | $38,860.98 | $77,337.2 | $38,476.22 | 99.01% |
Septarna Inc. (SEPN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Septarna Inc. ever had a stock split?
Septarna Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jeffrey T. Finer CEO | NASDAQ (NMS) Exchange | 81734D104 CUSIP |
| US Country | 130 Employees | - Last Dividend | - Last Split | 25 Oct 2024 IPO Date |
Overview
Septerna, Inc., initially known as GPCR NewCo, Inc., is a trailblazing clinical-stage biotechnology firm focused on the discovery and development of novel oral small molecule therapeutics. These product candidates are primarily aimed at addressing a wide range of diseases and conditions within the fields of endocrinology, immunology, inflammation, and metabolic diseases. The company’s groundbreaking work revolves around exploiting the potential of G protein-coupled receptors (GPCRs), a pivotal class of cell surface receptors involved in numerous physiological processes. Since its inception in 2019 and rebranding in June 2021, Septerna, Inc. has positioned itself at the forefront of developing cutting-edge treatments. Headquartered in South San Francisco, California, the company endeavors to create transformative therapies for patients worldwide.
Products and Services
- SEP-786 (Oral Small Molecule PTH1R Agonist for Hypoparathyroidism)
- SEP-631 (Oral Small Molecule MRGPRX2 NAM for Chronic Spontaneous Urticaria and Other Mast Cell Diseases)
- TSHR Program (Oral Small Molecule TSHR NAM for Graves' Disease and Thyroid Eye Disease)
- Oral Small Molecule Single- and Multi-Incretin Receptor Agonists for Metabolic Disorders
Targeting a challenging and underserved medical condition, SEP-786 is designed as an oral agonist of the parathyroid hormone receptor (PTH1R). By mimicking the actions of the natural parathyroid hormone, this innovative treatment aims to address hypoparathyroidism, a condition characterized by insufficient levels of parathyroid hormone, leading to numerous physiological disturbances.
SEP-631 emerges as a novel therapeutic approach, acting as a negative allosteric modulator (NAM) of the MRGPRX2 receptor. This receptor is implicated in the activation of mast cells, which play a significant role in allergic reactions and conditions like chronic spontaneous urticaria. By modulating this pathway, SEP-631 presents a promising potential to treat and manage mast cell-related diseases effectively.
Addressing autoimmune conditions associated with thyroid function, the TSHR Program focuses on developing oral small molecule therapies that act as negative allosteric modulators of the thyroid-stimulating hormone receptor (TSHR). These innovative treatments are geared towards offering new hope to patients suffering from Graves' disease and thyroid eye disease, conditions often marked by hyperactivity of the thyroid gland and related complications.
In the battle against metabolic disorders, such as obesity and type 2 diabetes, Septerna, Inc. delves into the potential of incretin receptor agonists. By exploring both single- and multi-incretin receptors, the company's research aims to unlock new pathways for treating these conditions. The incretins, which are hormones that play a crucial role in glucose metabolism, offer a promising avenue for developing therapies that could significantly impact patients’ quality of life.
